Table 6 Therapeutic management during the stay in the ICU
Therapeutic treatment | N = 45 n(%) |
|---|---|
Required antibiotic | 31 (68,9) |
• Carbapenem | 15 (33,1) |
• Piperacillin / tazobactam | 12 (26,7) |
• Vancomycin | 10 (22,2) |
• Ceftriaxone | 7 (15,5) |
• Ampicillin sulbactam | 5 (11,1) |
• Anti MRSA does not vancomycin * | 5 (11,1) |
• Ciprofloxacin | 4 (8,9) |
• Tuberculosis treatment | 3 (6,7) |
• Cefazolin | 3 (6,7) |
• Clarithromycin | 2 (4,4) |
• Polymyxin B | 1 (2,2) |
• Penicillin | 1 (2,2) |
Required Antifungal | 7 (15,5) |
• Fluconazole | 4 (8,9) |
• Voriconazole | 2 (4,4) |
• Caspofungin | 1 (2,2) |
• Anidulafungin | 1 (2,2) |
Immunosuppression | |
• Pulses Methylprednisolone | 22 (48,9) |
• Cyclophosphamide | 18 (40,0) |
• Immunoglobulin | 7 (15,5) |
• Rituximab | 3 (6,7) |
Supports | |
• Mechanical ventilation | 14 (31,1) |
• Days, Medium (RIQ) | 5,5 (3–17,75) |
• Dialytic support | 16 (35,5) |
• Vasopressor support | 9 (20,0) |
Procedures | 17 (37,7) |
Red blood cells transfusion | 31 (68,9) |
Platelet aferesis | 7 (15,5) |
Fresh frozen plasma | 8 (17,7) |
Plasmaferesis | 1 (2,2) |